Ministry of Higher Education & Scientific Research

Alsalam University College

Medical Laboratory Technique Department

Hyperkalemia in patients with chronic renal failure

Submitted to Alsalam University College

In partial Fulfillment of the Requirement's for the Degree of Bachelors of

Medical Laboratory Technique

By:

Supervised by:
‫‪Scientific Degree‬‬

‫‪Name:‬‬

‫‪1445 A.H‬‬ ‫‪2024 A.D‬‬

‫‪Supervisor Certification‬‬

‫بسم هللا الرحمـن الرحيم‬

‫ْع َم َف َن َّل‬ ‫َو َم ُك‬

‫﴿ ا ِب م ِّم ن ِّن ٍة ِم ال هۖ ﴾‬
‫ّل‬
‫صدق ال ه العلي العظيم‬
٥٣ - ‫النحل‬

ACNOWLEDGEMENT

The researchers extend their gratitude to all who contributed to the

completion of this research. First and foremost, we are grateful to the
University of San Carlos for providing us with a learning opportunity that
enabled the development of valuable life lessons including patience,
perseverance, teamwork, resilience, cooperation, and a relentless pursuit of
knowledge.

Secondly, we wish to express deep and sincere appreciation to Ms. Jovelyn

Q. Yu for her invaluable guidance, support, advice, comments, suggestions,
and provisions that greatly assisted in the successful completion of this study.
It was indeed a privilege and honor to work and study under her mentorship.

We also wish to convey our utmost gratitude to our parents for their
unwavering love, prayers, support, and sacrifices. Without their selfless
devotion and support, this achievement would not have been possible.

Special thanks are extended to Almighty God for granting us the strength,
knowledge, ability, and opportunity to undertake this research study. Without
His guidance and mercy, our endeavors, including this research, would not
have come to fruition. To God be the Glory!

Lastly, we extend our thanks to all individuals who supported us directly or

.indirectly in completing this research work

ABSTRACT:

Hyperkalemia poses a significant risk to patients with end-stage renal disease

(ESRD) undergoing maintenance dialysis, particularly those on hemodialysis.
Current management strategies primarily involve dialysis, dietary potassium
restriction, and avoidance of hyperkalemia-inducing medications. This review
examines the challenges associated with effectively managing hyperkalemia in
this population, emphasizing the potential role of newer potassium-binding
agents, such as patiromer and sodium zirconium cyclosilicate, in reducing the
need for strict dietary restrictions and mitigating the risk of life-threatening
hyperkalemia. Furthermore, the abstract discusses the variability in
hyperkalemia prevalence among chronic kidney disease (CKD) patients, citing
major risk factors such as lower estimated glomerular filtration rate (eGFR), use
of renin-angiotensin-aldosterone system inhibitors (RAASis), diabetes, older
age, and male gender. While sodium polystyrene sulfonate has historically been
used to manage hyperkalemia in CKD, its efficacy lacks robust clinical
evidence and is associated with rare but serious colonic complications. The
newer potassium-binding agents demonstrate efficacy and safety in non-
emergent hyperkalemia treatment, potentially allowing continued use of
RAASis in affected CKD patients. However, the long-term impact of this
approach on morbidity, mortality, and quality of life necessitates further
investigation, particularly in comparison to alternative strategies such as
RAASis down-titration and/or diuretic up-titration.

INTRODUCTION:

The elevation of serum potassium (SK) levels represents a common hydro-

electrolytic imbalance frequently observed in individuals diagnosed with
chronic kidney disease (CKD) (1, 2). This complication carries an unfavorable
and potentially life-threatening prognosis due to its cardiotoxic effects and
increased risk of mortality (3). The incidence of hyperkalemia (HK) escalates
with the progression of CKD, posing a significant threat to the safety of affected
patients (4). Moreover, the likelihood of HK occurrence amplifies with the
utilization of medications prescribed for their favorable cardio-renal effects,
particularly renin-angiotensin-aldosterone system inhibitor drugs (RAASI),
often undermining their clinical efficacy in CKD patients (5). In hospitalized
individuals, both CKD and prolonged HK independently serve as negative
prognostic indicators. The rise in K+ levels is prevalent among non-dialysis
(ND) CKD patients, with variations in prevalence primarily influenced by
factors such as patient comorbidities and the estimated glomerular filtration rate
(EGFR). In studies conducted within the general population, the incidence of
hyperkalemia varies considerably, with its manifestation influenced by a
multitude of factors. Patients with chronic kidney disease (CKD), particularly
those with concurrent Diabetes Mellitus (DM), exhibit heightened susceptibility
to potassium (K+) disorders, notably hyperkalemia (HK) attributable to the
advancement of renal dysfunction or the utilization of renin-angiotensin-
aldosterone system inhibitors (18). Compared to the general populace,
individuals with DM are at increased risk of HK due to various diabetic-related
alterations, including hyporeninemic hypoaldosteronism, hyperosmolality,
insulin deficiency, and the administration of medications for managing
comorbidities (19). Consequently, it is imperative for clinicians to focus on
managing HK effectively to optimize therapeutic approaches for its chronic
treatment in non-dialysis CKD patients. This endeavor can be facilitated by the
adoption of novel potassium-binding agents. The objective of this review is to
delineate the pivotal role of HK management in CKD, elucidating the
underlying pathophysiological mechanisms driving HK, and further elucidating
its prognostic implications on mortality and renal deterioration. With the
expanding array of treatment modalities available, we aim to provide a
comprehensive overview of the epidemiology, pathogenesis, etiology, and
classifications of HK in CKD, with particular emphasis on potassium exchange
resins.

THE RESEARCH GOALS:

1. Evaluate the incidence rate of hyperkalemia in patients with chronic renal

failure.

2. Review current strategies used to manage hyperkalemia in these patients.

3. Analyze the challenges and difficulties that physicians may encounter in

managing hyperkalemia in this patient population.

4. Provide recommendations to improve the management of hyperkalemia in

patients with chronic renal failure.

Hyperkalemia on Peritoneal Dialysis and Hemodialysis

In this comprehensive review, we have incorporated various types of literature,

including original research papers, clinical trials, and reviews, that delve into
the pathophysiological mechanisms underlying hyperkalemia (HK) in chronic
kidney disease (CKD). We organize our findings starting with an exploration of
the pathophysiology of hyperkalemia in CKD, followed by a synthesis of
studies elucidating the prognosis and predictive factors of hyperkalemia, its
management strategies, and the emerging use of novel hypokalemic agents.[20]

Hyperkalemia is more common in patients undergoing dialysis compared to the

general population. Potassium levels tend to be lower in those on peritoneal
dialysis and higher in those on hemodialysis. Managing potassium levels is
crucial because extreme levels increase the risk of death. For individuals on
hemodialysis, maintaining normokalemia can be challenging due to significant
potassium fluctuations throughout the week.[21]

During a typical hemodialysis session, 70 to 100 mmol of potassium can be

removed. The National Institutes of Health recommends a daily dietary intake
of 60–85 mmol of potassium for adults without impaired potassium excretion.
Without residual urinary function, hyperkalemia is inevitable without dietary
modifications.[22]

For stable patients on maintenance hemodialysis, the definitive treatment for

hyperkalemia is dialysis. However, treatments like insulin or beta-2-agonists are
generally discouraged because they reduce potassium clearance during dialysis
and may lead to rebound hyperkalemia after treatment. The choice between
peritoneal dialysis and hemodialysis often depends on available access and
equipment.[23]

Hemodialysis is highly effective at reducing serum potassium concentrations,

typically lowering potassium by around one millimole per hour initially. The
clearance of potassium during dialysis depends significantly on the serum to
dialysate potassium concentration, although the optimum dialysate potassium
concentration is still debated. Higher bicarbonate concentrations in the dialysate
can cause more rapid reductions in serum potassium.[24]

Peritoneal dialysis can also effectively manage hyperkalemia but is less efficient
than hemodialysis. It may remove around half as much potassium as a standard
four-hour hemodialysis session in 24 hours. For patients with lower risk, high-
volume daily peritoneal dialysis can be an option, aiming to maximize
potassium clearance by using large fluid volumes and regular exchanges with
potassium-free dialysis fluid. Peritoneal dialysis also offers continuous therapy,
preventing rebound hyperkalemia and providing other potential benefits such as
increased hemodynamic stability and reduced need for vascular access.[25]

Definitions of Hyperkalemia:

Hyperkalemia is a common clinical problem with potentially fatal

consequences. The prevalence of hyperkalemia is increasing, partially due to
wide-scale utilization of prognostically beneficial medications that inhibit the
renin-angiotensin-aldosterone-system (RAASi) [26]

Hyperkalemia is the most common electrolyte disturbance observed in patients

with kidney disease, particularly in those in whom diabetes and heart failure are
present or are on treatment with renin–angiotensin–aldosterone system
inhibitors (RAASIs).[27]

Hyperkalemia (HK) is recognised as a major risk of potentially life threatening

cardiac arrhythmic complications. When an acute reduction of renal function
manifests,[28] both in patients with chronic kidney disease (CKD) and in those
with previously normal renal function, HK is the main indication for the
execution of urgent medical treatment and the recourse to extracorporeal
replacement therapies. In patients with end-stage renal disease, the presence of
HK not responsive to medical therapy is an indication at the beginning of
chronic renal replacement therapy. HK can also be associated indirectly with the
progression of CKD, because the finding of high potassium values leads to
withdrawal of treatment with RAASIs, which constitute the first choice nephro-
protective treatment.[29]

Hyperkalemia (HK) is a common finding in patients with kidney disease, due

to the effects of kidney dysfunction on potassium (K) homeostasis, and this
condition strongly impacts upon the quality of life and prognosis of these
patients.[30]

Causes of Hyperkalemia in End Stage Renal Disease (ESRD)

Chronic Hyperkalemia Caused by impairment of potassium excretory process

or increased potassium load, requires ongoing management to correct the
underlying disturbances in potassium balance, nonpharmacological
interventions. So, must induce potassium redistribution and excretion to
prevent the development or recurrence of hyperkalemia; monitor potassium
intake through diet. That because, your kidneys usually get rid of the extra
potassium and keep the level normal. If you have chronic kidney disease, your
kidneys may not be able to get rid of potassium properly so the level will go up.
[30]

In addition of that, there are other causes of high potassium level, like
Addison's disease, trauma or burn.And, some medications can cause high
potassium, like some water pills, beta blockers, some blood pressure
medications, and NSAIDs (non-steroidal anti-inflammatory drugs). [31]

DIAGNOSIS AND EVALUATION OF HYPERKALEMIA

Hyperkalemia is often asymptomatic, but patients may complain of nonspecific

symptoms such as palpitations, nausea, muscle pain, weakness, or paresthesia.
Moderate and especially severe hyperkalemia can lead to cardiotoxicity, which
can be fatal. The cause of hyperkalemia has to be determined to prevent future
episodes. Hyperkalemia is a condition characterized by an abnormally high
level of potassium in the blood. While potassium is a vital electrolyte for the
body's functions, high levels can disrupt the heart's rhythm and lead to serious
complications.[32]

Diagnosing and evaluating hyperkalemia involves a two-pronged approach:

Assessing the Severity of Hyperkalemia: This is primarily done through blood

tests to measure serum potassium levels. Levels exceeding 6.0 mEq per L (6.0
mmol per L) are considered clinically significant. An ECG (electrocardiogram)
is also crucial to assess the impact of high potassium on heart rhythm.
Characteristic changes in the ECG tracings can indicate the severity of
hyperkalemia.[33]

Identifying the Underlying Cause: Several factors can contribute to

hyperkalemia. Here's a breakdown of the diagnostic approach to identify the
cause:[34]

History and Physical Examination: A detailed medical history can provide clues
about potential causes. This includes conditions like chronic kidney disease,
medications (diuretics, ACE inhibitors), recent illnesses, and dietary habits.
Laboratory Tests:

Urine Studies: Urine tests like urine potassium and creatinine levels and urine
osmolality help assess kidney function and potassium excretion.

Other Blood Tests: Depending on the suspected cause, other blood tests like
blood urea nitrogen (BUN), creatinine, and adrenal hormone levels may be
helpful.

Here's a table summarizing the evaluation process:[35]

Purpose Test

Measures the amount of potassium in the Serum Potassium Level

blood

Evaluates the electrical activity of the heart ECG

for arrhythmias

Assesses urinary potassium excretion Urine Potassium and Creatinine

Levels

Evaluates kidney function Urine Osmolality

Assesses kidney function Blood Urea Nitrogen (BUN) and

Creatinine

Investigates potential hormonal imbalances Adrenal Hormone Levels

Treatment of hyperkalemia depends on the severity and underlying cause. It can
involve medications, dietary changes, dialysis, or a combination of theses.

MECHANISMS OF HYPERKALEMIA IN CKD[36]

As chronic kidney disease (CKD) progresses, the ability to excrete potassium

diminishes, exacerbating the challenge of maintaining potassium levels within
the normal range. Metabolic acidosis, a common occurrence in CKD, prompts
potassium to shift from intracellular to extracellular spaces, leading to elevated
serum potassium levels. Renal transplant recipients face similar risks, with
acidosis and calcineurin inhibitors both linked to hyperkalemia.[37]

Several comorbidities prevalent in CKD patients can further elevate serum

potassium levels. Acute kidney injury, characterized by a rapid decline in
glomerular filtration rate (GFR) and tubular flow, often accompanies a
hypercatabolic state, tissue damage, and heightened potassium levels,
particularly post-bleeding. Transfusions can also trigger acute potassium spikes,
necessitating emergency dialysis.[38]

Diabetes mellitus and cardiovascular disease, prevalent among CKD patients,

contribute to hyperkalemia through distinct pathways. Insulin deficiency and
hyperglycemia-induced hypertonicity diminish potassium transport into cells in
diabetic patients. Diabetes also correlates with hyponatremia
hypoaldosteronism, impairing potassium tubular secretion regulation.[39]

Cardiovascular ailments like hypertension, acute myocardial infarction, left

ventricular hypertrophy, and congestive heart failure often necessitate
medications that may elevate potassium levels. Drugs like cardiac glycosides
inhibit the Na+/K+ ATPase pump, leading to intracellular sodium exchange for
extracellular potassium, while heparin decreases aldosterone production, also
contributing to hyperkalemia. Notably, β2-adrenergic receptor blockers and
RAAS inhibitors, by curtailing renin production and potassium redistribution,
significantly influence potassium levels.[40]

Hyperkalemia poses grave consequences including arrhythmias, fatalities, and

discontinuation of implicated medications, potentially exacerbating underlying
conditions. Research underscores the association between serum potassium
levels exceeding 6.0 mmol/L and heightened risks of hospitalization and
mortality, with RAAS inhibitors and initial GFR playing pivotal roles in
hyperkalemia development.[41]

In clinical settings, RAAS inhibitors are widely prescribed for CKD patients
due to their beneficial effects on both cardiac and renal functions. Recent
review and meta-analysis indicate their kidney-protective role, especially in
CKD patients with proteinuria, marking them as the primary choice among
antihypertensive medications for this patient group. However, it's crucial to
acknowledge the risk of hyperkalemia associated with their use.[42]

Multiple clinical studies have linked RAAS inhibitors to elevated potassium

levels in CKD patients. Observational research revealed a 41% increase in
hyperkalemia occurrence among individuals using these medications.
Moreover, CKD patients face a higher risk of potassium elevation compared to
those without renal impairment.

For instance, the Renaal study, focusing on diabetic kidney disease patients
treated with Losartan or a placebo, noted a higher incidence of hyperkalemia in
the Losartan group. Similarly, another study found that patients on irbesartan
had a significantly higher hyperkalemia rate compared to those on placebo. This
mirrors findings in the general population without CKD, where hyperkalemia
correlates with increased cardiovascular events and mortality among those with
renal injury.[43]

Notably, combined ACEI and ARB therapy, though potentially beneficial, has
been associated with a heightened risk of hyperkalemia and acute kidney injury.
Consequently, clinicians often reduce or discontinue RAAS inhibitors due to
potassium level concerns. However, this strategy may yield adverse outcomes.
Research by Epstein et al. revealed that patients who received lower doses or
had RAAS inhibitors discontinued after hyperkalemia experienced more
adverse events related to CKD progression, initiation of dialysis, cardiovascular
incidents, or mortality compared to those maintaining the maximum tolerated
dose.

Balancing the risk of hyperkalemia with the cardiac and renal benefits of RAAS
inhibitors underscores the need for exploring alternative therapeutic options for
potassium level management.[44]

CLINICAL CONSEQUENCES[45]

Hyperkalemia can be classified according to the level of serum potassium into:

mild (5.5-6.0 mmol/L), moderate (6.0-6.5 mmol/L), and severe (>6.5 mmol/L).
Often, the clinical manifestations present as muscle weakness, paresthesia,
paralysis, nausea, dyspnea, hypotension, cardiac arrhythmia, or cardiac arrest.
One study showed that a serum potassium level >6.0 mmol/L was associated
with an increase of 30 times in the risk of mortality in one day; however, a level
>5.0 mmol/L was associated with long-term adverse events[46] Thomsen et al.
demonstrated that CKD patients who were not on dialysis and presented an
episode of hyperkalemia during the study period had a higher risk of
hospitalization due to ventricular arrhythmia, cardiac arrest, or other cardiac
eventsElectrocardiographic changes that can be observed are the peaked T
waves, prolonged PR interval, shorter QT interval, wider QRS complex,
absence of P wave, ventricular fibrillation, or ventricular tachycardia.
Additional laboratory tests are suggested, such as measurements of glucose,
sodium, blood gas, renin, aldosterone, and cortisol, in addition to an
electrocardiogram to assist in the choice of the best therapeutic option.

TREATMENT[46]

The management of hyperkalemia is divided into treatment for acute events and
chronic control of serum potassium.

The treatment for acute elevations of potassium aims to antagonize the action of
the ion in the cellular membrane and increase the potassium intake to the
intracellular space. These measures provide a temporary reduction or removal
of serum potassium. For that end, the therapeutic options are calcium gluconate,
insulin, sodium bicarbonate, b-adrenergic antagonists, diuretics, and/or
initiation or intensification of dialysis The focus of this review is not to provide
a detailed description of the treatment for acute hyperkalemia.[47]

In the treatment of non-severe hyperkalemia, for patients with CKD, dietary

guidance should be carried out by a team of nutritionists to identify and replace
foods rich in potassium and improve adherence to the dietary plan. It is worth
mentioning that in patients with CKD, the inadequate restriction of vegetable,
fruit, and liquid intake can cause or aggravate intestinal constipation, which
results in increased intestinal absorption of potassium.

Drugs associated with increased serum levels of potassium, such as beta-

blockers, mineralocorticoids receptor antagonists, calcineurin, nonsteroidal anti-
inflammatories, trimethoprim, and heparin should be adjusted or replaced in the
occurrence of this complication. Special attention should be taken regarding
RAAS inhibitors. As described above, these classes of drugs have a
fundamental role in cardiac-renal protection, and their suspension should take
into account the benefits of their use and the unfavorable outcomes that may
occur after their suspension or reduction

Some patients, after the initial measures, still maintain a high level of
potassium. For these, it is indicated to associate pharmacological approaches,
such as the use of sodium bicarbonate and the introduction or increase of
diuretics. The sodium bicarbonate dose varies between 3-5 grams per day and is
indicated only in patients with metabolic acidosis. It is worth noting that this
measure is poorly tolerated in patients with CKD patients in advanced stages
due to the risk of increased blood pressure and fluid retention The prescription
of diuretics should be made with caution and strict control to prevent
hypovolemia, hypotension, decreased GFR, and, consequently, the recurrence
of hyperkalemia In addition, exchange resins can be used .[48]

Sodium polystyrene sulfonate is a resin that exchanges sodium for potassium,

calcium, and ammonia and acts on the distal portion of the colon. The
administration is via oral or rectal route, through laxatives and enemas,
respectively. Clinical trials show that this resin is effective in the treatment of
mild hyperkalemia in patients with CDK in the early stages. Doses between 60-
80 grams lead to the fall of potassium serum levels by 0.9-1.7 mmol/L;
however, it takes a long time for the medication to act. In addition to this delay
of the therapeutic effect, the medication has frequent side effects, such as
gastrointestinal intolerance, hypocalcemia, and magnesium deficiency. Also, to
a lesser incidence, intestinal necrosis can occur. A recent study showed that
patients with CKD and GFR <30 mL/min who used sodium polystyrene
sulfonate had a higher risk of gastrointestinal events, including digestive
bleeding. Thus, the use of this medication in CKD patients is questionable due
to its uncertain efficacy, delayed effect, and the restricted use to mild
hyperkalemiaCalcium polystyrene sulfonate is another resin that exchanges
calcium for potassium. It also acts in the intestine and is administered via the
oral route. The drug information leaflet makes reference to a rectal use by
diluting it in sorbitol or methylcellulose. Its main side effect is constipation, but
there have also been reported occurrences of hypercalcemia and hypercalciuria.
A Korean group followed 247 patients with GFR of 3015 ± mL/min/1.73 m2,
for a period of 5-6 months and found a reduction in serum potassium levels (≥
0.3 mmol/L) in more than 70% of the participants who used the medication in a
dose of 2.5-15 grams a day[52].Wang et al. evaluated 58 patients on
hemodialysis who presented hyperkalemia (³5.5 mmol/L) for three weeks. In
61% of patients who used calcium polystyrene sulfonate, there was a decrease
in the serum level of potassium (<5.5 mmol/L)

Similar to calcium polystyrene sulfonate, patiromer is a resin that acts in the

colon, exchanging potassium for calcium. It is a new medication for the
treatment of chronic hyperkalemia in CKD patients, and studies have
demonstrated a good response to treatment. Like other ion exchange resins, the
main side effect described is constipation. In addition to that, there have also
been reports of mild hypomagnesemia[49] The Amethyst-DN study evaluated
306 diabetic patients with CKD in stages 3 and 4, who used RAAS inhibitors
for 52 weeks. The patients were stratified into mild and moderate hyperkalemia
according to the serum level of potassium at the beginning of the study. The
dose ranged from 4.2 to 16.8 grams twice a day, according to the initial
potassium level. In the group classified as mild, the reduction of the serum level
of potassium ranged between 0.35-0.55 mEq/L. In patients of the moderate
group, the reduction was 0.87-0.92 mEq/L. The reduction in both groups was
dose-dependent. In this study, they found a rate of 9.2% of worsening of CKD
among patients treated with the medication. The authors cannot say whether this
adverse event was secondary to the effect of drugs, an inherent progression of
CKD, or due to the increased doses of the RAAS inhibiting drugs used in the
treatment group (Pitt B, Bakris GL, Weir MR, Freeman MW, Lainscak M,
Mayo MR, et al. Long-term effects of patiromer for hyperkalaemia treatment in
patients with mild heart failure and diabetic nephropathy on angiotensin-
converting enzymes/angiotensin receptor blockers: results from AMETHYST-
DN. ESC Heart Fail. 2018;5(4):592-602.). Another large study evaluated
patients with CKD, GFR between 15-60 mL/min/1.73 m2, serum levels of
potassium between 5.1-6.6 mmol/L, and who were taking stable doses of all
medications, including RAAS inhibitors and diuretics. All patients used
patiromer for four weeks, with doses ranging between 4.2-8.4 grams twice a
day, according to the initial potassium level. After this stage, the patients were
divided into two groups, placebo and medication, for 8 more weeks of follow-
up. In the patiromer group, there was a reduction in serum levels of potassium
and an increased number of patients who were able to continue the use of
RAAS inhibitors during the study period. In the placebo group, 60% of
individuals had at least one episode of hyperkalemia during the second stage of
the study A small study with patients on hemodialysis demonstrated that the use
of patiromer decreased serum levels of potassium and phosphorus and increased
potassium in the stool. The reported that no adverse effect was observed during
the study period[50].Sodium zirconium cyclosilicate is a non-absorbable
compound of zirconium silicate that acts as a selective exchanger of potassium
and sodium for ammonia and hydrogen in the gastrointestinal tract, thus
increasing the stool excretion of potassium. The recommended initial dose is 10
grams, three times a day. Normokalemia is achieved in a period of 24-48 hours,
and it is recommended that the dose is reduced to maintain an optimal serum
level of potassium. A stage 3 study included 753 patients who had potassium
levels between 5.0-6.5 mmol/L and divided them into placebo and medication
groups. After 48 hours, there was a decrease in the level of potassium in the
group that used sodium zirconium cyclosilicate, and the decrease rate was dose-
dependent. In the maintenance stage, the potassium level remained within the
range of normality in patients from the medication group. Diarrhea was the
most common complication reported by the authors31. Kosiborod et al.
evaluated patients with CKD, failure, and diabetes who presented
hyperkalemia. The authors demonstrated that zirconium cyclosilicate was
effective both in the rapid reduction, with an average time of two hours to
decrease the level of potassium, and in the maintenance of normokalemia for up
to four weeks in patients with various degrees of hyperkalemia. Normokalemia
was achieved in 84% of patients after 24 hours, and in 98% after 48 hours of the
onset of treatment[51]In the recent Dialize study, the use of sodium zirconium
cyclosilicate in patients undergoing hemodialysis treatment was able to
maintain the serum level of potassium between 4.0-5.0 mmol/L in the period
between dialysis, with few records of adverse events[52].

Finally, in patients with pre-dialysis CKD, hyperkalemia resistant to

pharmacological approaches have an indication to start renal replacement
therapy. For patients undergoing dialysis and with potassium levels constantly
high, the use of dialysate with a low concentration (0 or 1 mmol/L) of
potassium is controversial since there have been reports of arrhythmia and
sudden death after hemodialysis sessions with these concentrations. Studies
suggest that these events could be related to the rapid fall in the extracellular
concentration of the ion. It is worth mentioning that these studies are all
observational, and there have been no formal clinical trials. Possible solutions to
this problem include prolonging the duration of the dialysis session, increasing
the frequency of dialysis sessions, using new modalities of hemodialysis and/or
potassium-binding resins. Another obstacle to the control of hyperkalemia in
CKD patients undergoing dialysis is the fluctuations in the serum level of
potassium. These fluctuations may not be detected, since, usually, serum
potassium is measured monthly, which would lead to the use of dialysate at an
inadequate concentration of potassium in the dialysis infusion.[53]
REFERENCES
01) Provenzano M, Minutolo R, Chiodini P, Bellizzi V, Nappi F, Russo D, et
al.. Competing-risk analysis of death and end stage kidney disease by
hyperkalaemia status in non-dialysis chronic kidney disease patients receiving
stable nephrology care. J Clin Med. (2018) 7:499. doi: 10.3390/jcm7120499.
02) De Nicola L, Di Lullo L, Paoletti E, Cupisti A, Bianchi S. Chronic
hyperkalemia in non-dialysis CKD: controversial issues in nephrology
practice. J Nephrol. (2018) 31:653–64. doi: 10.1007/s40620-018-0502-6.

03) Collins AJ, Reaven N, Mcgaughey K, Bushinsky DA. Association of serum

potassium with all-cause mortality in patients with and without heart failure,
chronic kidney disease, and/or diabetes. Am J Nephrol. (2017) 46:213–21. doi:
10.1159/000479802.
04) Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, et al.. The
frequency of hyperkalemia and its significance in chronic kidney disease. Arch
Intern Med. (2009) 169:1156–62. doi: 10.1001/archinternmed.2009.132.
05) Belmar Vega L, Galabia ER, Bada da Silva J, Bentanachs González M,
Fernández Fresnedo G, Piñera Haces C, et al.. Epidemiology of hyperkalemia in
chronic kidney disease. Epidemiología de la hiperpotasemia en la
enfermedadrenalcrónica. Nefrologia (Engl Ed). (2019) 39:277–86.
06) Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers
J, et al.. Prevalence and factors associated with hyperkalemia in predialysis
patients followed in a low-clearance clinic. Clin J Am Soc Nephrol.
(2012) 7:1234–41
07) Luo J, Brunelli SM, Jensen DE, Yang A. Association between serum potassium
and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol.
(2016) 11:90–100.
08) Kovesdy CP. Epidemiology of hyperkalemia: an update. Kidney Int Suppl
(2011). (2016) 6:3–6. doi: 10.1016/j.kisu.2016.01.002.
09) Chang AR, Sang Y, Leddy J, Yahya T, Kirchner HL, Inker LA, et
al.. Antihypertensive medications and the prevalence of hyperkalemia in a large
health system. Hypertension. (2016) 67:1181–8.
10) Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related
metabolic complications. J Am Soc Nephrol. 2009; 20:164–171.
11) Stefano Bianchi, Filippo Aucella, and others,Management of hyperkalemia in
patients with kidney disease: a position paper endorsed by the Italian Society of
NephrologyJ Nephrol. 2019; 32(4): 499–516.

12) Davide costa, Gemma patella, and others, Hyperkalemia in CKD: an overview
of available therapeutic strategies, Volume 10 - 2023
13) Kovesdy CP. Management of hyperkalemia: an update for the internist. Am J
Med. (2015) 128:1281–7. doi: 10.1016/j.amjmed.2015.05.040
14) van de Luijtgaarden MWM, Noordzij M, Tomson C, Couchoud C, Cancarini G,
Ansell D, et al.. Factors influencing the decision to start renal replacement
ther(2018) 32;197-197-212.
15) sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M, et
al.. Prevalences of hyperuricemia and electrolyte abnormalities in patients with
chronic kidney disease in Japan: a nationwide, cross-sectional cohort study
using data from the Japan Chronic Kidney Disease Database (J-CKD-
DB). PLoS One. (2020) 15:1–16.
16) Goia-Nishide K, Coregliano-Ring L, Rangel ÉB. Hyperkalemia in diabetes
mellitus setting. Diseases. (2022) 10:20.
17) Sousa AG, Cabral JV, El-Feghaly WB, de Sousa LS, Nunes
AB. Hyporeninemic hypoaldosteronism and diabetes mellitus: pathophysiology
assumpt nd implications for management. World J. Diabetes. (2016) 7:101–20.
18) Palmer BF. Regulation of potassium homeostasis. Clin J Am Soc Nephrol.
(2015) 10:1050–60.
19) Kim GH. Pharmacologic treatment of chronic hyperkalemia in patients with
chronic kidney disease. Electrolyte Blood Press. 2018;17(1):1-6.
20) Sousa AG, Cabral JV, El-Feghaly WB, de Sousa LS, Nunes
AB. Hyporeninemic hypoaldosteronism and diabetes mellitus: pathophysiology
assumptions, clinical aspects and implications for management. World J.
Diabetes. (2016) 7:101–20.
21) Levi M, Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate,
and magnesium homeostasis. Clin J Am Soc Nephrol. (2015).
22) Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis, and management of
hyperkalemia. Pediatr Nephrol. March 2011; 26:377-384.
23) (Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat
Rev Nephrol. 2014;10(11):653-62).
24) Provenzano, M, Minutolo, R, Chiodini, P, Bellizzi, V, Nappi, F, Russo, D, et al.
Competing-risk analysis of death and end stage kidney disease by
hyperkalaemia status in non-dialysis chronic kidney disease patients receiving
stable nephrology care. J Clin Med. (2018) 7:499. doi: 10.3390/jcm7120499
25) De Nicola, L, Di Lullo, L, Paoletti, E, Cupisti, A, and Bianchi, S. Chronic
hyperkalemia in non-dialysis CKD: controversial issues in nephrology
practice. J Nephrol. (2018) 31:653–64. doi: 10.1007/s40620-018-0502-6.
26) De Nicola, L, Di Lullo, L, Paoletti, E, Cupisti, A, and Bianchi, S. Chronic
hyperkalemia in non-dialysis CKD: controversial issues in nephrology
practice. J Nephrol. (2018) 31:653–64. doi: 10.1007/s40620-018-0502-6
27) Einhorn, LM, Zhan, M, Hsu, VD, Walker, LD, Moen, MF, Seliger, SL, et al.
The frequency of hyperkalemia and its significance in chronic kidney
disease. Arch Intern Med. (2009) 169:1156–62. doi:
10.1001/archinternmed.2009.132
28) Belmar Vega, L, Galabia, ER, Bada da Silva, J, Bentanachs González, M,
Fernández Fresnedo, G, Piñera Haces, C, et al. Epidemiology of hyperkalemia
in chronic kidney disease. Epidemiología de la hiperpotasemia en la
 enfermedadrenalcrónica. Nefrologia (Engl Ed). (2019) 39:277–86. doi:
10.1016/j.nefroe.2018.11.014
29) Sarafidis, PA, Blacklock, R, Wood, E, Rumjon, A, Simmonds, S, Fletcher-
Rogers, J, et al. Prevalence and factors associated with hyperkalemia in
predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol.
(2012) 7:1234–41. doi: 10.2215/CJN.01150112
30) Luo, J, Brunelli, SM, Jensen, DE, and Yang, A. Association between serum
potassium and outcomes in patients with reduced kidney function. Clin J Am
Soc Nephrol. (2016) 11:90–100. doi: 10.2215/CJN.01730215
31) Kovesdy, CP . Epidemiology of hyperkalemia: an update. Kidney Int Suppl
(2011). (2016) 6:3–6. doi: 10.1016/j.kisu.2016.01.002
32) Chang, AR, Sang, Y, Leddy, J, Yahya, T, Kirchner, HL, Inker, LA, et al.
Antihypertensive medications and the prevalence of hyperkalemia in a large
health system. Hypertension. (2016) 67:1181–8. doi:
10.1161/HYPERTENSIONAHA.116.07363
33) Cupisti A, Brunori G, Di Iorio BR, D'Alessandro C, Pasticci F, Cosola C, et al.
Nutritional treatment of advanced CKD: twenty consensus statements. J
Nephrol. 2018;31(4):457-73.).
34) Epstein M. Hyperkalemia constitutes a constraint for implementing renin-
angiotensin-aldosterone inhibition: the widening gap between mandated
treatment guidelines and the real-world clinical arena. Kidney Int Suppl (2011).
2016;6(1):20-8.

35) Yu MY, Yeo JH, Park JS, Lee CH, Kim GH. Long-term efficacy of oral
calcium polystyrene sulfonate for hyperkalemia in CKD patients. PLoS One.
2017;12(3):e0173542.
36) Drugs Ther. (2018) 32:197–212. doi: 10.1007/s10557-018-6783-0
37) Pecoits-Filho, R, Fliser, D, Tu, C, Zee, J, Bieber, B, Wong, MMY, et al.
Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its
 determinants in patients with advanced CKD under nephrologist care. J Clin
Hypertens (Greenwich). (2019) 21:991–1001. doi: 10.1111/jch.1356.
38) Sofue, T, Nakagawa, N, Kanda, E, Nagasu, H, Matsushita, K, Nangaku, M, et
al. Prevalences of hyperuricemia and electrolyte abnormalities in patients with
chronic kidney disease in Japan: a nationwide, cross-sectional cohort study
using data from the Japan Chronic Kidney Disease Database (J-CKD-
DB). PLoS One. (2020) 15:1–16. doi: 10.1371/journal.pone.0240402
39) Fitch, K, Woolley, JM, Engel, T, and Blumen, H. The clinical and economic
burden of hyperkalemia on medicare and commercial payers. Am Health Drug
Benefits. (2017) 10:210–02.
40) Provenzano, M, De Francesco, M, Iannazzo, S, and Garofalo, C. Cost-analysis
of persistent hyperkalaemia in non-dialysis chronic kidney disease patients
under nephrology care in Italy. Int J Clin Pract. (2020) 74:e13475. doi:
10.1111/ijcp.13475
41) Miao, Y, Dobre, D, and Heerspink, HJL. Increased serum potassium affects
renal outcomes: A post hoc analysis of the reduction of endpoints in NIDDM
with the angiotensin II antagonist losartan (RENAAL) trial. Diabetologia.
(2011):44–50. doi: 10.1007/s00125-010-1922-6
42) Georgianos, PI, and Agarwal, R. Revisiting RAAS blockade in CKD with
newer potassium-binding drugs. Kidney Int. (2018) 93:325–34. doi:
10.1016/j.kint.2017.08.038
43) Fried, LF, Emanuele, N, Zhang, JH, Brophy, M, Conner, TA, Duckworth, W, et
al. Combined angiotensin inhibition for the treatment of diabetic
nephropathy. N Engl J Med. (2013) 369:1892–903. doi:
10.1056/NEJMoa1303154
44) Lockwood, C . Dietary interventions for adults with chronic kidney disease: a
Cochrane review summary. Int J Nurs Stud. (2018) 88:163–4. doi:
10.1016/j.ijnurstu.2018.02.006
45) Vijayakumar S, Butler J, Bakris GL. Barriers to guideline mandated renin-
angiotensin inhibitor use: focus on hyperkalemia. Eur Heart J Suppl.
2019;21(Suppl A):A20-7.
46) Leslie V. Simon; Muhammad F. Hashmi; Mitchell W. Farrell, Hyperkalemia,
September 4, 2023
47) Vijayakumar S, Butler J, Bakris GL. Barriers to guideline mandated renin-
angiotensin inhibitor use: focus on hyperkalemia. Eur Heart J Suppl.
2019;21(Suppl A):A20-7.
48) Thomsen RW, Nicolaisen SK, Hasvold P, Sanchez RG, Pedersen L, Adelborg
K, et al. Elevated potassium levels in patients with chronic kidney disease:
occurrence, risk factors and clinical outcomes: a Danish population-based
cohort study. Nephrol Dial Transplant. 2018;33(9):1610-20.).
49) Caravaca-Fontán F, Valladares J, Díaz-Campillejo R, Barroso S, Luna E,
Caravaca F. Association of hyperkalemia with clinical outcomes in advanced
chronic kidney disease. Nefrologia. 2019;39(5):513-22.
50) Renato Watanabe , Hyperkalemia in chronic kidney disease, Rev. Assoc. Med.
Bras. 66 (Suppl 1) . 2020 .
51) Bushinsky DA, Rossignol P, Spiegel DM, Benton WW, Yuan J, Block GA, et
al. Patiromer decreases serum potassium and phosphate levels in patients on
hemodialysis. Am J Nephrol. 2016;44(5):404-10.).
52) Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G,
et al. Sodium zirconium cyclosilicate in hyperkalemia. N Eng J Med.
2015;372(3):222-31.
53) Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D,
et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28
days among outpatients with hyperkalemia: the HARMONIZE randomized
clinical trial. JAMA. 2014;312(21):2223-33.